The human PC346 xenograft and cell line panel: A model system for prostate cancer progression

被引:74
作者
Marques, RB
van Weerden, WM
Erkens-Schulze, S
de Ridder, CM
Bangma, CH
Trapman, J
Jenster, G
机构
[1] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus MC, Dept Pathol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands
关键词
prostate carcinoma; androgen receptor; antiandrogen; hormone resistance; xenograft; cell line;
D O I
10.1016/j.eururo.2005.12.035
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Prostate cancer (PC) model systems that reflect the different disease stages are essential for studying the development and progression of PC and for testing new treatment modalities. This review summarizes the establishment and characterization of the PC346 progression model and compares it to other available human PC cell lines and xenografts. Methods: The PC346 model was derived from the transurethral resection of a primary prostate tumor. Tumor samples were subcutaneously implanted into athymic mice, which resulted in the development of a series of xenografts from which in vitro cell cultures were established. Results: The PC346 panel includes sublines with hormone-response characteristics that range from androgen-sensitive to androgen-independent (AI) growth. In vivo and in vitro selection of androgen-sensitive lines under androgen-depleted conditions replicated the clinically relevant relapse phenomenon, and resulted in a series of modifications in the androgen-receptor (AR) pathway: AR mutation, overexpression, and downregulation. Conclusions: The PC346 panel reproduces many biological characteristics of the different phases of clinical PC and the most common AR modifications observed in hormone-refractory tumors, being a valuable addition to the limited collection of available model systems. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:245 / 257
页数:13
相关论文
共 71 条
[1]  
Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO
[2]  
2-2
[3]   Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer [J].
Brown, RSD ;
Edwards, J ;
Dogan, A ;
Payne, H ;
Harland, SJ ;
Bartlett, JMS ;
Masters, JRW .
JOURNAL OF PATHOLOGY, 2002, 198 (02) :237-244
[4]  
Buchanan G, 2001, CLIN CANCER RES, V7, P1273
[5]  
Buhler Kent R., 1999, Journal of Urology, V161, P58
[6]   BCL-2 in prostate cancer: A minireview [J].
Catz, SD ;
Johnson, JL .
APOPTOSIS, 2003, 8 (01) :29-37
[7]   Molecular determinants of resistance to antiandrogen therapy [J].
Chen, CD ;
Welsbie, DS ;
Tran, C ;
Baek, SH ;
Chen, R ;
Vessella, R ;
Rosenfeld, MG ;
Sawyers, CL .
NATURE MEDICINE, 2004, 10 (01) :33-39
[8]   Evidence of independent origin of multiple tumors from patients with prostate cancer [J].
Cheng, L ;
Song, SY ;
Pretlow, TG ;
Abdul-Karim, FW ;
Kung, HJ ;
Dawson, DV ;
Park, WS ;
Moon, YW ;
Tsai, ML ;
Linehan, WM ;
Emmert-Buck, MR ;
Liotta, LA ;
Zhuang, ZP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (03) :233-237
[9]  
Chlenski A, 2001, PROSTATE, V47, P66
[10]  
Craft N, 1999, CANCER RES, V59, P5030